News headlines about Amedisys (NASDAQ:AMED) have been trending somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedisys earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the health services provider an impact score of 46.433702164666 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Amedisys (AMED) Given a $70.00 Price Target by Jefferies Group Analysts (americanbankingnews.com)
- Amedisys CEO: We Want to Change the Managed Care Game (homehealthcarenews.com)
- Amedisys (AMED) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- What to Expect from Amedisys in 2018 (finance.yahoo.com)
- How Amedisys Has Performed Financially (finance.yahoo.com)
Shares of Amedisys stock opened at $61.43 on Friday. The stock has a market capitalization of $2,086.67, a P/E ratio of 69.81, a PEG ratio of 1.05 and a beta of 0.62. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 0.15. Amedisys has a 1 year low of $45.60 and a 1 year high of $65.91.
A number of research analysts have recently commented on the company. BidaskClub upgraded Amedisys from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a report on Tuesday, February 6th. TheStreet lowered Amedisys from a “b” rating to a “c+” rating in a report on Wednesday, February 28th. Robert W. Baird set a $66.00 price target on Amedisys and gave the stock a “hold” rating in a report on Thursday, March 1st. Finally, Oppenheimer upped their price target on Amedisys from $68.00 to $63.00 and gave the stock an “outperform” rating in a report on Thursday, March 1st. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Amedisys currently has an average rating of “Buy” and a consensus target price of $63.18.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.